InvestorsHub Logo

Jonjones325

01/03/17 9:03 PM

#86549 RE: seventhwave #86531

There is such a low bar for Rett. I think any improvement will be seen as a positive and would pave the way for approval. Besides, I believe the trial is being run as a phase 2. Many times, especially with orphan indications, the FDA will convert it to a pivotal if the results are positive. Missling also stated this in the conference call.

With our safety profile, the quality of life benefits seen so far and the preclinical epilepsy data, I believe we have a pretty decent shot. However, I agree that it will definitely look bad if we fail with Rett.

FooBarAndGrill

01/04/17 9:39 AM

#86599 RE: seventhwave #86531

For Rett's, I believe there is a good chance of success. The genetic mutation of Rett's Syndrome was well replicated in the pre-clinical mouse models. See http://www.anavex.com/?news=anavex-presents-preclinical-results-of-anavex-2-73-in-rett-syndrome

McMagyar

01/04/17 3:39 PM

#86633 RE: seventhwave #86531

seventh..
failure at RETT won't take us back anywhere..
NO FEAR!

We can not lose by trying to help RETT SYNDROME girls..
simply can not lose ANYTHING that matters.

WALK as our CEO walks..NO FEAR